FDA grants accelerated approval to Rybrevant Faspro for head and neck cancerNov 5Regulatory decisionamivantamab and hyaluronidase-lpujamivantamab-vmjw
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
J&J reports Q3 2026 results, raises full-year sales and EPS guidanceOct 13Quarterly updateJohnson & Johnson
Halozyme posts record Q2 2026, raises full-year guidance on royalty growthAug 6Quarterly updateHalozyme Therapeutics
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply dealAug 3Quarterly updateORIC Pharmaceuticals